|
FY2026
12 months to Mar 31, 2026
|
FY2025
12 months to Mar 31, 2025
|
FY2024
12 months to Mar 31, 2024
|
|
|---|---|---|---|
| Net (loss)/profit | |||
| Non-cash adjustment: | |||
| Fair value (gain)/loss on convertible note | |||
| Fair value loss/(gain) on warrant liability | |||
| Fair value (gain)/loss on promissory notes | |||
| Fair value loss on warrant exchange | |||
| Fair value gain on Psyence Labs Ltd | |||
| Fair value loss on Digital Assets | |||
| Share of losses from Associate | |||
| Gain on debt settlement | |||
| Share-based compensation | |||
| Third party advisors share issuance | |||
| Depreciation | |||
| Foreign exchange | |||
| Listing expense | |||
| Transaction expenses | |||
| Changes in working capital: | |||
| Other receivables | |||
| Loan receivable | |||
| Prepaids | |||
| Accounts payable and accrued liabilities | |||
| Cash used in operating activities | |||
| Additions to equipment | |||
| Increase in restricted cash | |||
| Investment in Digital Assets | |||
| Investment in Psyence Labs Ltd | |||
| Cash used for investing activities | |||
| Payment of promissory note | |||
| Proceeds received from convertible note | |||
| Payment of promissory note | |||
| Net proceeds received from ELOC | |||
| Net proceeds received for unit issuances | |||
| Cash provided from financing activities | |||
| Change in cash and cash equivalents | |||
| Cash and cash equivalents, beginning of year | |||
| Cash and cash equivalents, end of year |
Loading...
